Attached files
| file | filename |
|---|---|
| 10-K - Protagenic Therapeutics, Inc.\new | v178944_10k.htm |
| EX-31.1 - Protagenic Therapeutics, Inc.\new | v178944_ex31-1.htm |
| EX-31.2 - Protagenic Therapeutics, Inc.\new | v178944_ex31-2.htm |
| EX-21.1 - Protagenic Therapeutics, Inc.\new | v178944_ex21-1.htm |
| EX-32.1 - Protagenic Therapeutics, Inc.\new | v178944_ex32-1.htm |
| EX-10.21 - Protagenic Therapeutics, Inc.\new | v178944_ex10-21.htm |
| EX-10.20 - Protagenic Therapeutics, Inc.\new | v178944_ex10-20.htm |
| EX-10.22 - Protagenic Therapeutics, Inc.\new | v178944_ex10-22.htm |
| EX-10.23 - Protagenic Therapeutics, Inc.\new | v178944_ex10-23.htm |
CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board
of Directors of
Atrinsic,
Inc.:
We
consent to the incorporation by reference in Registration Statement Nos.
333-145933 and 333-164465 on Form S-8 of Atrinsic, Inc. and subsidiaries of our
report dated March 30, 2010, with respect to the consolidated balance sheets of
Atrinsic, Inc. and subsidiaries as of December 31, 2009 and 2008, and the
related consolidated statements of operations, equity, comprehensive loss, and
cash flows for each of the years in the two-year period ended December 31, 2009,
which report appears in the December 31, 2009 Annual Report on Form 10-K of
Atrinsic, Inc. and subsidiaries.
/s/ KPMG
LLP
New York,
New York
March 30,
2010
EX-4